At Aurigene, we offer capabilities and expertise for various unit operations applicable to a broad range of APIs. Our vast manufacturing footprint allows us the flexibility to have a variety of unit operations suitable for various types of APIs. We provide most of these unit operations at lab scale as well as in GMP sites and containment facilities. All our manufacturing facilities are equipped with handling major unit operations like reactions, mixing, extraction, distillation, crystallization, filtration and drying. Aurigene has a broad capability of powder processing for API manufacturing. Apart from this, the manufacturing facility has the capability to handle some exclusive unit operations like special drying using ATFD, Spray Dryer for heat sensitive materials, Column Chromatography for advanced purification of racemic mixture, hydrogenation, lyophilization etc.
Spray drying is a method of producing a dry powder from a liquid by rapidly drying with a hot air. Typically spray drying as an operation is used for thermally sensitive compounds or for obtaining finer particle size distribution or to get an amorphous polymorph.
At Aurigene, we provide spray drying capabilities at the lab as well as manufacturing scale. We have spray dryers up to a maximum evaporation rate of 50 kg/hour in non-potent as well as high potent sites.
ATFDs are used for converting crystalline to amorphous form. Typically, this operation is used for compounds that are heat sensitive or have less residence time or for the development of an amorphous form of the compound. At Aurigene, we provide ATFD services in lab scale as well as in plant scale. We have ATFDs at a maximum capacity of 3.5 sq. m. We have ATFD operation for regular API as well as high potent APIs.
Micronization is the process of reducing the diameter of API particles to enhance the solubility properties of the compound. All manufacturing facilities are equipped with particle size regulating equipment including multi-mill, air jet mill or micronizer, sifter, and blenders. We have micronizers in high potent and steroidal blocks also.
Aurigene has broad capabilities for scale-up of different kinds of hydrogenation reactions with different type of catalysts and at wide ranges of pressure ratings. Maximum capacity can be handled in the range of 5KL for the hydrogenator and maximum pressure handles upto 35 bars. The manufacturing sites are also capable of small-scale hydrogenation with a minimum capacity of 20L in the GMP environment.
At Aurigene multiple reactors are available at the manufacturing facilities to handle cryogenic reactions. The reactors are ranging from 200 L to 11000 L (3000 Gallon) capacities. Cryo reactors are also available in steroid manufacturing facilities at Aurigene. Both Stainless steel and Haste alloy reactors are available at manufacturing sites.
Reverse-phase HPLC is the most versatile and efficient method of peptide purification. The working principle is that hydrophobic molecules are retained from the aqueous mobile phase through strong interactions with hydrophobic hydrocarbon ligands. Greater the height of packing, the better the separation of impurities. However, increased column height requires increased amounts of solvents. We have RP-HPLCs in lab scale as well as in plant scale with a capacity ranging from 150 mm diameter to 1000 mm diameter.
Ion exchange chromatography separates molecules based on their respective charged groups. It retains analyte molecules on the column based on ionic interactions. The ion exchange chromatography matrix consists of positively and negatively charged ions. In the ion exchange chromatography, some of the impurities will get absorbed and the compound with enriched purity will come in the form of a solution. We have ion exchange chromatography on lab scale as well as production scale with a capacity of 350 mm diameter.
As a part of peptide molecule development and manufacturing, both manual and auto peptide synthesizers are available which can accommodate multiple scale of peptide compounds. This is supported by multiple capacity of Ion exchange columns and RP HPLC columns as a part of the purification technique. Finally, the material is lyophilized to get the final compound. All these unit operations can be carried out in both development and manufacturing area. From the lab 20 to 50 g of non GMP material can be provided to the clients and 100 to multi kilos can be supplied to customer with various batch sizes.
Variety of unit operations in lab and plant scale
Experts scientists, process, and lead engineers
QbD-based process design
Flexible scale of operations
Unit operations in containment
NOVEMBER 16, 2023
Both natural and unnatural catastrophic events inflict negative consequences due to the ever-increasing interconnectedness of the global economy. Those consequences are certain to last for longer duration. e.g.; The Covid-19 pandemic is still having a negative impact on the global economy. Maintaining continuity is critical for all businesses, but perhaps no othe...Read More
The pharma industry is evolving and a demand for integrated CDMOs, which can help accelerating innovations, is part of the evolution....Read More
Aurigene Pharmaceutical Services has a legacy of +20 years in developing and manufacturing compounds under cGMP. Our manufacturing plants are spread across 3 continents with facilities in India, UK, and Mexico. ...Read More
Introduction: Any new chemical entity (NCE) needs to undergo various stages of development such as preclinical and clinical trials before drug product is approved by regulatory agencies and available for patient. Formulations developed during early phases are simple formulations to enable phase appropriate studies like screening, dose ranging, toxicological and d...Read More
A robust and metal catalyst-free method has been developed for the general and green synthesis of racemic (3,4-dihydro-2H-benzo[b][1,4] oxazin-2-yl)methanol derivatives. This simple, mild and practical method involves the reaction of 2-aminophenols with ()-epichlorohydrin in the presence of NaOH in water at room temperature. The reaction features high regioselec...Read More
Scalable alternate end-game strategies for the synthesis of the anti-COVID drug molecule Nirmatrelvir (1,PF-07321332) have been described. The first involves a direct synthesis of 1 via amidation of the carboxylic acid 7 (suitably activated as a mixed anhydride with either pivaloyl chloride or T3P) with the ...Read More
Cholecalciferol, also known as Vitamin D3, is widely prescribed for the treatment osteomalacia and osteoporosis . It also plays a key role in calcium and phosphorus homeostasis and skeletal mineralization . IUPAC name of Cholecalciferol is (3β, 5Z, 7E)- 9,10-secocholesta-5,7,10(19)-trien-3-ol, whose molecular weight is 384.64 g/mol and its molecular formul...Read More
Mutations in MEK1/2 have been described as a resistance mechanism to BRAF/MEK inhibitor treatment. We report the discovery of a novel ATP-competitive MEK1/2 inhibitor with efficacy in wildtype (WT) and mutant MEK12 models. Starting from a HTS hit, we obtained selective, cellularly active ...Read More
You are about to leave Aurigene Pharmaceutical Services and affiliates website. Aurigene Pharmaceutical Services assumes no responsibility for the information presented on the external website or any further links from such sites. These links are presented to you only as a convenience, and the inclusion of any link does not imply endorsement by Aurigene Pharmaceutical Services.
If you wish to continue to this external website, click Proceed.